Financial Performance - The company's revenue for Q3 2023 was ¥193,338,268.99, a decrease of 16.67% compared to the same period last year[5] - The net profit attributable to shareholders was -¥16,948,088.97, reflecting a decline of 168.31% year-on-year[5] - The operating income for the first nine months of 2023 was ¥827,063,956.04, representing a growth of 16.25% year-on-year[8] - Total operating revenue for Q3 2023 reached ¥827,063,956.04, an increase of 16.2% compared to ¥711,438,394.76 in Q3 2022[20] - Net profit for Q3 2023 was ¥135,495,906.37, representing a 30.4% increase from ¥103,838,963.13 in the same period last year[21] - The company reported an investment loss of ¥11,963,049.57, compared to a loss of ¥8,136,319.73 in the previous year[21] - The total comprehensive income for the period reached CNY 138,782,369.86, compared to CNY 107,008,293.50 in the previous period, reflecting an increase of approximately 29.6%[22] - Basic and diluted earnings per share increased to CNY 0.35 from CNY 0.27, representing a growth of 29.6%[22] Cash Flow and Liquidity - The net cash flow from operating activities was ¥79,904,989.91, down 34.70% from the previous year[5] - Cash flow from financing activities resulted in a net outflow of CNY -470,812.35, an improvement from CNY -61,863,857.48 in the previous period[24] - Cash received from sales of goods and services amounted to CNY 1,060,260,519.97, up from CNY 669,663,038.96, marking an increase of about 58.2%[23] - Total cash outflow from operating activities was CNY 1,040,828,737.57, compared to CNY 598,638,878.74 in the previous period, an increase of approximately 74.0%[24] - The net cash flow from investing activities was negative at CNY -4,533,911.05, an improvement from CNY -38,948,649.08 in the previous period[24] - Cash and cash equivalents at the end of the period totaled CNY 511,952,047.47, up from CNY 258,146,823.18, reflecting an increase of approximately 98.0%[24] - The company reported cash inflow from investment activities of CNY 29,340,062.89, compared to CNY 6,674,457.42 in the previous period, an increase of about 339.5%[24] Assets and Liabilities - Total assets at the end of Q3 2023 amounted to ¥3,050,715,989.39, a slight decrease of 0.30% from the end of the previous year[5] - Total liabilities decreased to ¥611,865,671.36 from ¥756,559,066.03, indicating a reduction of 19.2%[18] - The company's equity attributable to shareholders increased by 6.10% to ¥2,413,012,171.69 compared to the end of last year[5] - The equity attributable to shareholders of the parent company increased to ¥2,413,012,171.69, up from ¥2,274,229,801.83, reflecting a growth of 6.1%[18] - The company's total assets as of Q3 2023 were ¥3,050,715,989.39, slightly down from ¥3,059,913,477.69 at the end of Q2 2023[18] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 23,460[10] - The total number of shares held by the top 10 unrestricted shareholders includes 100,878,929 shares held by Gao Yaping, accounting for 25.11% of total shares[11] - The company has a total of 69,822,051 restricted shares, with 4,620,000 shares released during the period[14] Operational Insights - The company did not report any new product developments or market expansion strategies during this quarter[5] - The company plans to continue expanding its market presence and developing new products, although specific figures were not disclosed in the report[15] - The company is focused on strategic initiatives to enhance operational efficiency and market competitiveness, although detailed strategies were not specified in the report[15] Inventory and Receivables - Accounts receivable rose to CNY 94,709,673.49, up from CNY 93,407,726.74, indicating a slight increase of 1.4%[16] - Inventory levels increased significantly to CNY 238,385,210.14 from CNY 197,369,370.03, reflecting a growth of about 20.8%[16] - The company reported a decrease in financing receivables, which fell to CNY 157,636,001.92 from CNY 391,459,984.49, a decline of approximately 59.8%[16] - The company has maintained a stable level of other receivables, which increased to CNY 28,224,765.21 from CNY 25,368,560.96, a growth of about 7.3%[16] - The company’s trading financial assets decreased to CNY 38,468,443.39 from CNY 63,809,837.46, a decline of approximately 39.7%[16] Research and Development - Research and development expenses increased to ¥40,018,123.05, compared to ¥30,020,328.40, marking a rise of 33.3%[20] Audit Status - The company has not undergone an audit for the third quarter report[25]

证券代码：300434 证券简称：金石亚药 公告编号：2023-027 1、审议通过了《2023 年第三季度报告》 经审核，监事会认为公司董事会编制和审核公司《2023 年第三季度报告》的 程序符合法律、行政法规及中国证监会的规定，报告内容真实、准确、完整地反 映了上市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 《2023 年第三季度报告》详见公司同日在巨潮资讯网及公司指定信息披露 媒体发布的相关公告。 表决结果：3 票同意，0 票反对，0 票弃权，本议案获得通过。 四川金石亚洲医药股份有限公司 第四届监事会第十次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 四川金石亚洲医药股份有限公司（以下简称"公司"）第四届监事会第七次 会议于 2023 年 10 月 27 日上午以通讯表决表决方式召开，会议通知已于 2023 年 10 月 24 日以电子邮件或网络方式发出。本次会议应出席监事 3 人，实际出席监 事 3 人。本次会议由监事会主席汪进先生主持。本次会议的召集、召开程序符合 有关法律、行政法规、部门规 ...

证券代码：300434 证券简称：金石亚药 公告编号：2023-026 四川金石亚洲医药股份有限公司 第四届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 经研究讨论，会议达成如下决议： 1、审议通过了《2023 年第三季度报告》 《2023 年第三季度报告》详见公司同日在巨潮资讯网及公司指定信息披露 媒体发布的相关公告。 公司监事会对公司《2023 年第三季度报告》进行审核并发表了审核意见， 具体意见内容详见公司同日在巨潮资讯网及公司指定信息披露媒体发布的相关 公告。 表决结果：11 票同意，0 票反对，0 票弃权，本议案获得通过。 三、备查文件 1、《第四届董事会第十次会议决议》。 特此公告。 一、董事会会议召开情况 四川金石亚洲医药股份有限公司（以下简称"公司"）第四届董事会第十次 会议于 2023 年 10 月 27 日上午以通讯表决方式召开。本次董事会会议通知已于 2023 年 10 月 24 日以电子邮件或网络方式发出。会议应出席董事 11 名，实际 出席董事 11 名。本次会议由董事长魏宝康先生主持。本次会议的召集、召开 ...

证券代码：300434 证券简称：金石亚药 四川金石亚洲医药股份有限公司 投资者关系活动记录表 编号：2023-004 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活 | □媒体采访 □业绩说明会 | | 动类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | √其他（2023 年半年度业绩交流会） | | 华安证券 参与单位名称 | 谭国超 李雨涵 刘洪飞 | | 民生医药 | 王班 宋丽莹 易美娟 | | 及人员姓名 瓦琉咨询 | 杨云添 梁羽蒙 符传宏 滕美忻 | | 健顺投资 | 张琦悦 | | 时间 2023 | 年 8 月 29 日 下午 15：00-16：00 | | 地点 线上会议 | | | 上市公司接待 | 董事、副总裁、董事会秘书 林 强 | | 人员姓名 财务总监 | 王庆国 纪要内容： | | 况。 | 一、由公司董事、副总裁、董事会秘书林强致欢迎辞，介绍公司基本情 | | 投资者关系活 每股收益 | 2023 年上半年，公司实现营业收入 6.34 亿元，同比增长 32.18%；基本 0.39 元/股，同比上升 89.44%。 ...

Financial Performance - The company's operating revenue for the first half of 2023 reached ¥633.73 million, representing a 32.18% increase compared to ¥479.43 million in the same period last year[28]. - Net profit attributable to shareholders was ¥155.73 million, up 89.45% from ¥82.20 million year-on-year[28]. - The net profit after deducting non-recurring gains and losses was ¥149.63 million, an increase of 137.42% compared to ¥63.02 million in the previous year[28]. - Basic earnings per share rose to ¥0.3876, reflecting an increase of 89.44% from ¥0.2046 in the same period last year[28]. - The company's total assets at the end of the reporting period were ¥3.09 billion, a 1.04% increase from ¥3.06 billion at the end of the previous year[28]. - Net assets attributable to shareholders increased by 6.85% to ¥2.43 billion from ¥2.27 billion at the end of the previous year[28]. - The net cash flow from operating activities decreased by 10.59% to ¥101.26 million from ¥113.26 million in the previous year[28]. - The weighted average return on equity improved to 6.62%, up from 3.89% in the same period last year[28]. - The company's revenue for the reporting period reached ¥633,725,687.05, representing a year-on-year increase of 32.18% due to a rebound in market demand[48]. - The gross profit margin for the pharmaceutical manufacturing sector was 67.33%, an increase of 4.65% compared to the previous year, with revenue from this sector amounting to ¥577,820,675.91[50]. Product Portfolio and Market Position - The company reported a significant reliance on its main products, particularly the "Kuaike" cold medicine series, which accounted for a high percentage of both revenue and gross profit during the reporting period[5]. - The company has over 90 drug production approval numbers and 6 health food production approval numbers, indicating a diverse product portfolio[6]. - The "Kuaike" brand has maintained a leading position in the cold medicine market, ranking first in the annual comprehensive statistics for non-prescription drugs in the "cold category" for three consecutive years from 2020 to 2022[36]. - The company has developed a product line covering various therapeutic areas, including respiratory, digestive, orthopedic, and pediatric medicine, with a focus on cold and flu relief, gastrointestinal health, and nutritional supplements[37]. - The "Kuaike" and "Xiaokuaike" brands have become household names in China, with significant brand recognition and competitive advantages, having received the "well-known trademark" honor[37]. - The company is expanding its market share in health products by utilizing online sales channels and has established a B2C e-commerce platform on major platforms like Tmall and JD[38]. - The company is actively promoting prescription drug development and expanding its product line through academic promotion and agent expansion[39]. - The company has successfully developed and launched the traditional Chinese medicine "Xuduan Zhuanggu Capsule," which is classified as a Category II new drug and targets primary osteoporosis, indicating a broad market potential[40]. Research and Development - The company plans to enhance its R&D efforts with over ten ongoing projects, focusing on adult upper respiratory and calcium supplement series products[6]. - Research and development investment increased by 27.27% to ¥27,863,062.95, driven by higher clinical trial and external research costs[48]. - The company is actively developing high-end raw materials such as calcium carbonate and expanding its market presence both domestically and internationally, focusing on customized, high-quality products[40]. - The company is committed to expanding its capabilities in the new materials and machinery sector, focusing on innovative solutions for market demands[42]. - The company is enhancing its product technology through customer feedback, driving iterative upgrades in its offerings[41]. Financial Strategy and Investments - The company does not plan to distribute cash dividends or issue bonus shares for the reporting period[8]. - The company has not made any changes to its registered address or contact information during the reporting period[25]. - The company has ongoing major non-equity investments, including the Zhejiang Yafeng Pharmaceutical production base project, with a total investment of ¥23,106,000[59]. - The company has not engaged in any derivative investments or entrusted loans during the reporting period, reflecting a conservative financial strategy[64]. - The company has reported a significant increase of 102.55% in net cash flow from investment activities, amounting to ¥1,071,131.45, influenced by financial investments[48]. Environmental Compliance - The company strictly adheres to environmental protection laws and standards, with subsidiaries included in the key pollutant discharge unit list[80]. - The company has implemented continuous monitoring of wastewater discharge, ensuring compliance with the GB040600 standards[88]. - The company achieved compliance with the GB16297-1996 air pollution discharge standards, with no exceedances reported[87]. - The company has established a stable discharge flow, ensuring that emissions remain within permissible limits[88]. - The company is committed to maintaining environmental standards and has not reported any exceedances in pollutant discharge[87]. Corporate Governance and Shareholder Relations - The company has not experienced any environmental pollution incidents or disputes during the reporting period, adhering to national and local environmental protection laws[104]. - The company actively engages in investor relations activities to ensure long-term harmonious development with shareholders[102]. - The annual shareholders meeting had a participation rate of 57.89% on May 26, 2023[74]. - The company has not conducted any repurchase transactions during the reporting period[138]. - The total number of shareholders at the end of the reporting period is 23,687[137].

四川金石亚洲医药股份有限公司 独立董事关于第四届董事会第九次会议相关事项的独立意见 1、报告期内，未发现控股股东及其他关联方非经营性占用公司资金情况。 根据中国证券监督管理委员会《上市公司独立董事规则》、《深圳证券交易所 创业板股票上市规则》、《深圳证券交易所上市公司自律监管指引第 2 号—创业板 上市公司规范运作》和四川金石亚洲医药股份有限公司（以下简称"公司"）《公 司章程》、《独立董事工作制度》的有关规定，我们作为公司独立董事，对公司 2023 年上半年度资金占用及对外担保情况及公司第四届董事会第九次会议审议 的《关于与参股公司签订技术开发合同暨关联交易的议案》进行了认真审查，在 仔细审阅公司提供的相关资料，并听取有关人员说明的基础上，基于独立、客观 判断的原则，现发表意见如下： 一、对公司 2023 年上半年度资金占用及对外担保情况的独立意见 2、报告期内，未发现新增对外担保，也不存在以前期间发生并延续到报告 期的对外担保。截止 2023 年 6 月 30 日，公司对外担保余额为人民币 0 元。 综上，我们认为公司严格执行了《上市公司监管指引第 8 号——上市公司资 金往来、对外担保的监管要求》（证监 ...

证券代码：300434 证券简称：金石亚药 公告编号：2023-026 四川金石亚洲医药股份有限公司 关于与参股公司签订技术开发合同暨关联交易的公告 本公司及董事会全体成员、保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、关联交易概述 基于四川金石亚洲医药股份有限公司（以下简称"公司"）业务发展需要，为 进一步丰富产品管线，助力公司建立产品差异化竞争优势，打造新的技术壁垒和利 润增长点，公司全资公司浙江亚克药业有限公司（以下简称"亚克药业"）与公司 参股公司杭州领业医药科技有限公司（以下简称"领业医药"）分别签订《技术开 发合同》，委托领业医药进行骨化三醇软胶囊、布洛芬软胶囊、ω-3 脂肪酸乙酯 90 软胶囊项目的技术开发工作，交易金额合计人民币 1,412 万元（含税）。 领业医药为公司之参股公司，公司持有其 28.96%的股份。鉴于公司董事长、 总经理魏宝康先生现担任领业医药董事长，公司董事盛晓霞女士现担任领业医药 董事兼总经理。此外，公司第一大股东高雅萍女士直接持有领业医药 25.66%的股 份。根据《深圳证券交易所创业板股票上市规则》有关规定，领业医药为公司关联 法人。 ...

证券代码：300434 证券简称：金石亚药 公告编号：2023-022 四川金石亚洲医药股份有限公司 第四届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 四川金石亚洲医药股份有限公司（以下简称"公司"）第四届董事会第九次 会议于 2023 年 8 月 27 日上午 9：30 以通讯表决方式召开。本次董事会会议通知 已于 2023 年 8 月 24 日以电子邮件或网络方式发出。会议应出席董事 11 名，实 际出席董事 11 名。本次会议由董事长魏宝康先生主持。本次会议的召集、召开 程序符合《公司法》及《公司章程》的有关规定，会议表决合法有效。 二、董事会会议审议情况 经研究讨论，会议达成如下决议： 1、审议通过《2023 年半年度报告全文及摘要》 《2023 年半年度报告》详见公司同日在巨潮资讯网发布的相关公告，《2023 年半年度报告摘要》详见公司同日在巨潮资讯网及公司指定信息披露媒体发布的 相关公告。 公司监事会对公司《2023 年半年度报告全文及摘要》进行审核并发表了审 核意见；公司独立董事对控股股东及其 ...

公司负责人（法定代表人） ： 魏宝康 主管会计工作负责人 ： 王庆国 会计机构负责人 ： 王庆国 四川金石亚洲医药股份有限公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 | | | | | | | | | | | 单位：万元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 占用方与上市公司 | 上市公司核 | 2023年期初占用资 | 2023年半年度占用 | 2023年半年度占用资金 | 2023年半年度偿还 | 2023年期末占用资 | | | | 非经营性资金占用 | 资金占用方名称 | 的关联关系 | 算的会计科 | 金余额 | 累计发生金额（不 | 的利息（如有） | 累计发生金额 | 金余额 | 占用形成原因 | 占用性质 | | | | | 目 | | 含利息） | | | | | | | 控股股东、实际控制人及其附属企业 | | | | | | | | | | | | 小计 | - | - | - | | | | | | | - | | 前控股股东 、实际控制人及其附属 ...

根据中国证券监督管理委员会《上市公司独立董事规则》、《深圳证券交易所 创业板股票上市规则》、《深圳证券交易所上市公司自律监管指引第 2 号—创业板 上市公司规范运作》和四川金石亚洲医药股份有限公司（以下简称"公司"）《公 司章程》、《独立董事工作制度》的有关规定，我们作为公司独立董事，对拟提交 公司第四届董事会第九次会议审议的《关于与参股公司签订技术开发合同暨关联 交易的议案》进行了事先审查。基于独立、客观判断的原则，现发表事前认可意 见如下： 四川金石亚洲医药股份有限公司 独立董事关于第四届董事会第九次会议相关事项 的事前认可意见 本次关联交易定价公允，符合公司业务发展需要，有利于进一步丰富公司产 品管线，不存在损害公司及全体股东、特别是中小股东利益的情形。我们一致同 意将《关于与参股公司签订技术开发合同暨关联交易的议案》提交公司第四届董 事会第九次会议审议。董事会审议本次关联交易事项时，关联董事魏宝康先生、 盛晓霞女士应当回避表决。 （以下无正文） 二〇二三年八月二十七日 独立董事： ______________ ______________ ______________ ______________ 马 ...